Shalini Sharp

Shalini Sharp joined our Board of Directors as a member of the Audit Committee in September 2024 and was appointed a member of the Nominating and Corporate Governance Committee in January 2025.

Mrs. Sharp is a leading financial executive with extensive experience in the pharmaceutical and investment banking industries. Mrs. Sharp currently serves as a board member of Neurocrine Biosciences and Organon & Co. Previously, she served on the boards of Mirati Therapeutics, Sutro Biopharma, Precision Biosciences, Panacea Acquisition Corp., Array Biopharma, and Agenus Inc.

Mrs. Sharp previously served as Chief Financial Officer and Executive Vice President at Ultragenyx as well as Chief Financial Officer and Vice President at Agenus. She previously held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs.

Mrs. Sharp holds a B.A. and an MBA from Harvard University.